About Us
Biophytis is clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases.
Our Science
Our therapeutic approach is aimed at targeting and activating key biological resilience pathways that can protect against and counteract the effects of the multiple biological and environmental stresses, including inflammatory, oxidative and metabolic stresses that lead to age-related diseases.
Pipeline
Our lead drug candidate, Sarconeos (BIO101), is an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and DMD. Our second drug candidate, Macuneos (BIO201), is an orally administered small molecule in development for the treatment of retinal diseases, including dry AMD and Stargardt disease.
News
02 May 2019

Biophytis Presented A Poster at The Association for Research in Vision and Ophthalmology Annual Meeting. Read the Press Release

17 April 2019

Interview with Stanislas Veillet, CEO of Biophytis, on the Web TV www.labourseetlavie.com realized by the journalist Didier Testot